---
schema_version: "secwatch.filing_event.v1"
accession: "0001672688-26-000118"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2026-06-24T10:32:11+00:00"
generated_at: "2026-06-24T10:35:09.367709+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Absci reports positive interim Phase 1 data for ABS-201; half-life ≥65 days supports dosing 2-3 times/6 months

## Summary
- No serious adverse events; TEAEs were mild except one moderate headache deemed unrelated to treatment.
- Estimated half-life of at least 65 days across all four SAD cohorts (150–1800 mg IV).
- MAD portion in androgenetic alopecia participants initiated; interim PoC data expected H2 2026.
- Phase 2 trial for endometriosis planned later this year.
- 32 healthy volunteers enrolled in four SAD cohorts; data cutoff June 8, 2026.

## SEC filing metadata
- accession: 0001672688-26-000118
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2026-06-24T10:32:11+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/0001672688-26-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/absc-20260624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001672688-26-000118
- JSON: https://secwatch.observer/filing/0001672688-26-000118.json
- Plain text: https://secwatch.observer/filing/0001672688-26-000118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.